Johnson & Johnson (JNJ) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-28..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-28..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-28..
Borrowing debt
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 37.34B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | Commercial Paper |
| Cash and current securities | 20.76B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities · Commercial Paper |
| Total assets | 201.06B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | (m) | (m) | $37.34B | (m) | $20.76B | $201.06B | (m) |
| 2026-03-29 | (m) | (m) | (m) | $37.53B | (m) | $22.05B | $200.89B | (m) |
| 2025-12-28 | (m) | (m) | $2.00B | $39.44B | (m) | $20.10B | $199.21B | (m) |
| 2025-09-28 | (m) | (m) | (m) | $39.41B | (m) | $18.56B | $192.82B | (m) |
| 2025-06-29 | (m) | (m) | (m) | $39.23B | (m) | $18.88B | $193.39B | (m) |
| 2025-03-30 | (m) | (m) | (m) | $38.35B | (m) | $38.78B | $193.67B | (m) |
| 2024-12-29 | (m) | (m) | $1.75B | $30.65B | (m) | $24.52B | $180.10B | (m) |
| 2024-09-29 | (m) | (m) | (m) | $31.29B | (m) | $20.30B | $178.29B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $31.64B | (m) | $25.48B | $181.09B | (m) |
| 2024-05-15 | (m) | (m) | (m) | (m) | $3.60B | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | $25.08B | (m) | $26.22B | $171.97B | (m) |
| 2023-12-31 | (m) | (m) | $1.47B | $25.88B | (m) | $22.93B | $167.56B | (m) |
| 2023-10-01 | (m) | (m) | (m) | $26.05B | (m) | $23.51B | $166.06B | (m) |
| 2023-07-02 | (m) | (m) | (m) | $33.90B | (m) | $28.50B | $191.69B | (m) |
| 2023-04-02 | (m) | (m) | (m) | $34.93B | (m) | $24.61B | $195.97B | (m) |
| 2023-01-01 | (m) | (m) | $1.55B | $26.89B | (m) | $23.52B | $187.38B | (m) |
| 2022-10-02 | (m) | (m) | (m) | $27.60B | (m) | $34.08B | $175.12B | (m) |
| 2022-07-03 | (m) | (m) | (m) | $28.29B | (m) | $32.57B | $177.72B | (m) |
| 2022-04-03 | (m) | (m) | (m) | $28.85B | (m) | $30.39B | $178.35B | (m) |
| 2022-01-02 | (m) | (m) | $2.13B | $29.98B | (m) | $31.61B | $182.02B | (m) |
| 2021-10-03 | (m) | (m) | (m) | $30.13B | (m) | $31.00B | $179.23B | (m) |
| 2021-07-04 | (m) | (m) | (m) | $30.31B | (m) | $25.31B | $176.44B | (m) |
| 2021-04-04 | (m) | (m) | (m) | $30.26B | (m) | $24.62B | $172.56B | (m) |
| 2021-01-03 | (m) | (m) | (m) | $32.63B | (m) | $25.18B | $174.89B | (m) |
| 2020-09-27 | (m) | (m) | (m) | $32.68B | (m) | $30.78B | $170.69B | (m) |
| 2020-06-28 | (m) | (m) | (m) | $25.06B | (m) | $19.14B | $158.38B | (m) |
| 2020-03-29 | (m) | (m) | (m) | $25.39B | (m) | $18.02B | $155.02B | (m) |
| 2019-12-29 | (m) | (m) | (m) | $26.49B | (m) | $19.29B | $157.73B | (m) |
| 2019-09-29 | (m) | (m) | (m) | $26.92B | (m) | $17.95B | $155.52B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $27.70B | (m) | $15.28B | $155.12B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $27.66B | (m) | $15.34B | $150.03B | (m) |
| 2018-12-30 | (m) | (m) | $2.60B | $27.68B | (m) | $19.69B | $152.95B | (m) |
| 2018-09-30 | (m) | (m) | (m) | $29.48B | (m) | $19.36B | $155.70B | (m) |
| 2018-07-01 | (m) | (m) | (m) | $29.41B | (m) | $18.14B | $155.37B | (m) |
| 2018-04-01 | (m) | (m) | (m) | $29.84B | (m) | $15.20B | $156.63B | (m) |
| 2017-12-31 | (m) | (m) | $1.50B | $30.68B | (m) | $18.30B | $157.30B | (m) |
| 2017-10-01 | (m) | (m) | (m) | $26.68B | (m) | $16.23B | $155.66B | (m) |
| 2017-07-02 | (m) | (m) | (m) | $27.36B | (m) | $12.85B | $152.81B | (m) |
| 2017-04-02 | (m) | (m) | (m) | $27.02B | (m) | $39.34B | $144.92B | (m) |
| 2017-01-01 | (m) | (m) | (m) | $22.44B | (m) | $41.91B | $141.21B | (m) |
| 2016-10-02 | (m) | (m) | (m) | $23.55B | (m) | $40.43B | $140.37B | (m) |
| 2016-07-03 | (m) | (m) | (m) | $24.54B | (m) | $42.58B | $139.81B | (m) |
| 2016-04-03 | (m) | (m) | (m) | $20.23B | (m) | $39.85B | $136.23B | (m) |
| 2016-01-03 | (m) | (m) | (m) | $12.86B | (m) | $38.38B | $133.41B | (m) |
| 2015-09-27 | (m) | (m) | (m) | $14.07B | (m) | $37.31B | $133.27B | (m) |
| 2015-06-28 | (m) | (m) | (m) | $14.09B | (m) | $33.95B | $132.04B | (m) |
| 2015-03-29 | (m) | (m) | (m) | $14.94B | (m) | $31.32B | $128.59B | (m) |
| 2014-12-28 | (m) | (m) | (m) | $15.12B | (m) | $33.09B | $131.12B | (m) |
| 2014-09-28 | (m) | (m) | (m) | $13.15B | (m) | $33.01B | $132.10B | (m) |
| 2014-06-29 | (m) | (m) | (m) | $13.30B | (m) | $31.62B | $135.20B | (m) |
| 2014-03-30 | (m) | (m) | (m) | $13.34B | (m) | $29.39B | $133.33B | (m) |
| 2013-12-29 | (m) | (m) | (m) | $13.33B | (m) | $29.21B | $132.68B | (m) |
| 2013-09-29 | (m) | (m) | (m) | $9.75B | (m) | $25.23B | $126.93B | (m) |
| 2013-06-30 | (m) | (m) | (m) | $9.64B | (m) | $25.13B | $124.33B | (m) |
| 2013-03-31 | (m) | (m) | (m) | $11.36B | (m) | $21.67B | $121.54B | (m) |
| 2012-12-30 | (m) | (m) | (m) | $11.49B | (m) | $21.09B | $121.35B | (m) |
| 2012-09-30 | (m) | (m) | (m) | $11.43B | (m) | $19.77B | $118.95B | (m) |
| 2012-07-01 | (m) | (m) | (m) | $11.53B | (m) | $16.91B | $115.75B | (m) |
| 2012-04-01 | (m) | (m) | (m) | $13.01B | (m) | $33.85B | $116.19B | (m) |
| 2012-01-01 | (m) | (m) | (m) | $12.97B | (m) | $32.26B | $113.64B | (m) |
| 2011-10-02 | (m) | (m) | (m) | $13.03B | (m) | $30.93B | $111.82B | (m) |
| 2011-07-03 | (m) | (m) | (m) | $13.68B | (m) | $29.68B | $112.11B | (m) |
| 2011-04-03 | (m) | (m) | (m) | $9.26B | (m) | $26.87B | $108.15B | (m) |
| 2011-01-02 | (m) | (m) | $13.00M | $9.16B | (m) | $27.66B | $102.91B | (m) |
| 2010-10-03 | (m) | (m) | (m) | $9.18B | (m) | $22.13B | $98.25B | (m) |
| 2010-07-04 | (m) | (m) | (m) | $7.94B | (m) | $18.90B | $92.30B | (m) |
| 2010-04-04 | (m) | (m) | (m) | $8.06B | (m) | $18.01B | $93.44B | (m) |
| 2010-01-03 | (m) | (m) | (m) | $8.22B | (m) | $19.43B | $94.68B | (m) |
| 2009-09-27 | (m) | (m) | (m) | $8.26B | (m) | $14.34B | $91.56B | (m) |
| 2009-06-28 | (m) | (m) | (m) | $8.18B | (m) | $14.72B | $87.44B | (m) |
| 2008-12-28 | (m) | (m) | (m) | $8.12B | (m) | $12.81B | $84.91B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |